Daiichi Sankyo Will Focus R&D; Cardio Is Heart Of Combined Pipeline
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Japanese Pharma Sea Change: U.S. Development Takes Focus Over Licensing
Japanese pharma firms are changing the long-standing practice of out-licensing products in the U.S., with maturing U.S. operations now directly developing more than a dozen drugs in or near Phase III.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product